SCHEMBL1813299

SCHEMBL1813299

C1CCN(C2CC2)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26112589 1.00 L3MBTL3 (0.52)
SCHEMBL26117153 1.00 L3MBTL3 (0.52)
SCHEMBL26394048 0.96 L3MBTL3 (0.50)
SCHEMBL20756261 0.96 L3MBTL3 (0.50)
Iodide SCHEMBL26113855 0.96 L3MBTL3 (0.50)
Hydrochloric Acid SCHEMBL31467080 0.96 L3MBTL3 (0.50)
Iodide SCHEMBL31466960 0.96 L3MBTL3 (0.50)
Water SCHEMBL31467160 0.96 L3MBTL3 (0.50)
SCHEMBL827994 0.96
Methane SCHEMBL15974763 0.96

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9243002-B2 Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C MERCK SHARP & DOHME CORP. (US) 2016-01-26 US claimed
US-20150361101-A1 TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C MERCK SHARP & DOHME CORP. (US) 2015-12-17 US claimed
EP-2953456-A1 TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C Merck Sharp & Dohme Corp. (US) 2015-12-16 EP claimed
EP-2321317-B1 FUSED PYRROLIDINO-CYCLOPROPANE DERIVATIVES AS SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS MERCK PATENT GMBH (DE) 2014-12-24 EP claimed
WO-2014121416-A1 TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C MERCK SHARP & DOHME CORP. (US) 2014-08-14 WO claimed
WO-2014123793-A1 TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C MERCK SHARP & DOHME CORP. (US) 2014-08-14 WO claimed
US-8486964-B2 Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors MERCK PATENT GMBH (DE) 2013-07-16 US claimed
US-20110172265-A1 Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-07-14 US claimed
EP-2321317-A1 FUSED PYRROLIDINO-CYCLOPROPANE DERIVATIVES AS SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS Merck Patent GmbH (DE) 2011-05-18 EP claimed
WO-2010022850-A1 FUSED PYRROLIDINO-CYCLOPROPANE DERIVATIVES AS SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS MERCK PATENT GMBH (DE) 2010-03-04 WO claimed
US-20050148588-A1 LFA-1 antagonist compounds GENENTECH, INC. 2005-07-07 US claimed
US-6872735-B2 LFA-1 antagonist compounds GENENTECH, INC. (US) 2005-03-29 US claimed
US-20040058968-A1 LFA-1 antagonist compounds GENENTECH, INC. 2004-03-25 US claimed
US-6667318-B2 Antiinflammatory agents; autoimmune disease GENENTECH, INC. 2003-12-23 US claimed
US-20020119994-A1 LFA-1 Antagonist compounds GENENTECH, INC 2002-08-29 US claimed
US-12558350-B2 Compositions and methods for treatment BAUSCH + LOMB IRELAND LIMITED (IE) 2026-02-24 US disclosed
US-20250282768-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2025-09-11 US disclosed
EP-0539976-A1 Ethynyl-alanine-amino-diol compounds for treatment of hypertension G.D. Searle & Co. (US) 1993-05-05 EP disclosed
EP-0449989-A1 6,7 DIHYDROPYRROLO 3,4-c] PYRIDO 2,3-d] PYRIMIDINE DERIVATIVES Sloan-Kettering Institute For Cancer Research (US) 1991-10-09 EP disclosed
WO-1990007496-A1 6,7 DIHYDROPYRROLO[3,4-c] PYRIDO[2,3-d] PYRIMIDINE DERIVATIVES SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1990-07-12 WO disclosed